221 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27983835	81	Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.	Pfizer
27541357	58	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.	National University of Singapore
27816515	143	Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.	Merck
27490956	59	Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.	Merck
27288183	130	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.	Southeast University
27261178	32	Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.	Konkuk University
26951753	336	Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.	Novartis Institutes For Biomedical Research
26927423	58	Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.	Merck
26701356	100	Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.	Takeda Pharmaceutical
26632965	80	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.	Duke University School of Medicine
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26614408	106	Identification of azabenzimidazoles as potent JAK1 selective inhibitors.	Astrazeneca
26351728	96	Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.	Konkuk University
26320619	88	Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).	Bristol-Myers Squibb Pharmaceutical Research Institute
26288683	43	Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.	Bristol-Myers Squibb R & D
26288682	64	Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors.	Bristol-Myers Squibb Research & Development
26086931	38	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.	Shandong University
26231159	1	Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.	Chungnam National University
26222319	192	Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.	Nerviano Medical Sciences
26258521	104	Development of Selective Covalent Janus Kinase 3 Inhibitors.	Harvard Medical School
25987372	104	9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.	Bristol-Myers Squibb
25699576	42	Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.	University of South Florida
25415535	118	Inhibitors of c-Jun N-terminal kinases: an update.	Eberhard Karls Universit£T T£Bingen
24980703	296	Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.	Nerviano Medical Sciences
25453808	101	Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.	Bristol-Myers Squibb
25383627	85	Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.	Genentech
25369270	93	Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.	Galapagos
24417533	63	Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.	Pfizer
24139169	175	Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.	Nerviano Medical Sciences
24042009	89	Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.	Genentech
23265875	78	Design and synthesis of tricyclic cores for kinase inhibition.	Abbott Bioresearch Center
23214979	74	3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.	F. Hoffmann-La Roche
23127890	96	SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.	Exelixis
23103095	125	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.	Abbott Laboratories
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
21604762	152	Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymph	S*Bio
23116168	42	Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.	Sichuan University
23061660	92	Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.	Genentech
22698084	99	Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.	Genentech
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
22591402	127	Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.	Argenta Discovery
22339472	148	Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arth	S Bio
21155605	39	Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.	Novartis Institutes For Biomedical Research
21106455	60	Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.	Sri International
19648005	41	Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2) with osteogenic activity in osteoblast cells.	Amgen
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
18077425	197	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.	Harvard Medical School
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University of Oxford
18278858	93	Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.	Amgen
17935989	146	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.	Abbott Laboratories
22136433	67	7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.	Ludwig-Maximilians University of Munich
22087750	145	Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.	Amgen
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21942426	113	Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.	Merck
21936542	143	Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.	Novartis Institute For Biomedical Research
21470862	110	NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.	Nerviano Medical Sciences
24900250	81	Kinase Inhibition by Deoxy Analogues of the Resorcylic Lactone L-783277	TBA
21105711	79	Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.	Pfizer
21035336	42	5-amino-pyrazoles as potent and selective p38a inhibitors.	Bristol-Myers Squibb Research and Development
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
20346655	117	Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.	Abbott Laboratories
20231096	81	Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.	Novartis Institutes For Biomedical Research
20138510	60	2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.	Novartis Institutes For Biomedical Research
19926477	100	2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.	Abbott Laboratories
19053756	27	Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).	National Human Genome Research Institute
19035792	85	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.	Glaxosmithkline
17185414	30	Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.	Genomics Institute of The Novartis Research Foundation
16970394	147	Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.	Amgen
16216497	67	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.	Abbott Bioresearch Center
12482439	51	Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.	Merck Research Laboratories
11934592	24	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.	Merck Research Laboratories
32511913	141	Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.	Japan Tobacco
31980341	31	Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors.	Takeda Pharmaceutical
32253095	78	Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.	Pfizer
32462873	216	Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.	Gvk Biosciences
31843459	57	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.	Chia Tai Tianqing Pharmaceutical Group
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
30853331	95	Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.	China Pharmaceutical University
27491711	422	Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.	Merck And
27326341	142	Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors.	Leo Pharma
31266686	7	Small-molecule agents for the treatment of inflammatory bowel disease.	Gilead Sciences
31609613	244	Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.	TBA
31314518	356	Identification of	TBA
30113844	240	Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).	Pfizer
32297743	59	Discovery of (2	Astrazeneca
30891145	70	Identification of Imidazo[1,2-	Bristol-Myers Squibb
31693351	473	Discovery of 4	TBA
31318208	123	Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.	TBA
30565923	34	Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.	Eberhard Karls University T£Bingen
30901208	96	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.	Shandong University
30981578	46	Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.	East China University of Science & Technology
30926315	75	Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.	Central China Normal University
30987781	88	Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.	Southeast University
30891131	60	Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.	Bristol-Myers Squibb
31647655	114	Kinase Chemodiversity from the Arctic: The Breitfussins.	Uit - The Arctic University of Norway
30530193	64	Targeting the immunity protein kinases for immuno-oncology.	China Pharmaceutical University
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
31050421	48	Overview of Recent Strategic Advances in Medicinal Chemistry.	Shandong University
29870256	16	Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.	Genentech
28139931	85	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.	Pfizer
26505898	123	Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.	Novartis Institutes For Biomedical Research
26509640	234	Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.	Abbvie Bioresearch Center
30243158	80	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.	National University of Singapore
30423248	226	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.	Pfizer
30460842	111	Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.	Purdue University
30145050	27	Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.	Astellas Pharma
30139575	98	Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.	China Pharmaceutical University
29452839	82	Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.	Seoul National University
29293000	22	Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors.	University of Sharjah
29940115	55	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.	Second Military Medical University
29856615	85	Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.	Astrazeneca
29852068	86	Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.	Eberhard Karls University T£Bingen
28539220	198	Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.	Bristol-Myers Squibb Research and Development
28259529	31	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.	The Ohio State University
28927786	52	Discovery of highly potent, selective, covalent inhibitors of JAK3.	Bristol-Myers Squibb Research and Development
28830649	101	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.	Genentech
29156136	160	The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.	Merck
28953386	66	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.	National University of Singapore
29298069	206	Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.	Pfizer
22233543	70	New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.	Centre De Recherche De Gif
20939767	13	Synthesis and SAR comparative studies of 2-allyl-4-methoxy-1-alkoxybenzenes as 15-lipoxygenase inhibitors.	Mashhad University of Medical Sciences
28181373	14	Characterisation of Photoaffinity-Based Chemical Probes by Fluorescence Imaging and Native-State Mass Spectrometry.	Griffith University
28126289	11	Synthesis, biological evaluation and in silico studies of 5-(3-methoxybenzylidene)thiazolidine-2,4-dione analogues as PTP1B inhibitors.	Panjab University
27231830	27	Identification of novel acetylcholinesterase inhibitors: Indolopyrazoline derivatives and molecular docking studies.	Aimst University
11909603	1	T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist.	Takeda Chemical Industries
12210991	24	Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase.	New York University
16492568	12	Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.	Cyclacel
19758807	23	Indene-based frameworks targeting the 5-HT6 serotonin receptor: ring constraint in indenylsulfonamides using cyclic amines and structurally abbreviated counterparts.	Universitat De Barcelona
19179081	32	Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents.	Yale University
18243697	77	Identification of a potent new chemotype for the selective inhibition of PDE4.	Nih
19361197	54	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.	Universita Del Piemonte Orientale
18341273	16	Novel prostaglandin d synthase inhibitors generated by fragment-based drug design.	Astrazeneca
16242339	63	Thioureido N-acetyllactosamine derivatives as potent galectin-7 and 9N inhibitors.	Lund University
11520194	13	Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).	University of Illinois At Chicago
11731301	192	Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.	Axys Pharmaceutical
17201404	16	Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.	Glaxosmithkline
16434195	23	Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16982190	46	Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.	Glaxosmithkline
16913695	12	Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).	Istituto Di Cristallografia
12773032	4	3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.	University of Bologna
14552750	35	Identification of potent and novel small-molecule inhibitors of caspase-3.	Sunesis Pharmaceuticals